Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving ...

Last week, Hims and Hers announced it would sell its version of a weight loss pill for as low as $49.

Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".

The approval from the Saudi Food and Drug Authority allows the company to enter Saudi Arabia, one of the largest markets for ...

Despite their huge popularity, GLP-1 injury lawsuits citing the drugs as a cause for a host of severe GI issues and even ...

News and commentary from the endocrinology world ...

Drug maker Novo Nordisk has filed a lawsuit against telehealth provider Hims and Hers over alleged copycat versions of its weight-loss and obesity medications.

The free-for-all-era of weight-loss copycats is ending, but will likely morph into something else.

Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Legal pressures ...

Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine ...

Dr Reddy’s plans to launch generic semaglutide in March 2026, potentially lowering prices in India’s fast-growing weight-loss ...